Scandinavian ChemoTech proceeds to the second round of “Horizon 2020” and is awarded a 50 000 EUR contribution

The ChemoTech D-EECP project for pain treatment of patients suffering from metastases in the spine, proceeds to the second round of “Horizon 2020” and is awarded a 50 000 Euro contribution to cover application costs for phase 2.

Horizon 2020 is the most extensive EU program for research and innovation ever. The purpose of the program is to achieve more breakthroughs, discoveries and world news by supporting good ideas from the lab to advance to the market.

The process includes several steps, where the first is a 50 000 EUR contribution to cover application costs. ChemoTech will receive the funds after the contract has been received and signed. The continued development process can give additionally up to three million EUR.

“Succeeding in the first phase in our Horizon application is very satisfying. The timing could not be better, considering that after we have passed the very important commercial milestone for IQwave™ and have got the first clinical report published, we are ready to continue our important R&D work”, says Mohan Frick, CEO of ChemoTech.

For more information please contact:

Mohan Frick, CEO

Tele: +46 (0)10-218 93 00

Mail: info@chemotech.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Tuesday March 26th 2019 at 16.22 (CET).

Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, 
E-mail: 
ca@vhcorp.se

Scandinavian ChemoTech AB (publ)

www.chemotech.se

ChemoTech är ett life science-företag som vilar på stor medicinsk expertis och tekniskt kunnande. Vår senaste lansering av IQwave™ är en innovation inom elektroporation, som är anpassad för Elektrokemoterapibehandling av olika typer av tumörer. ChemoTech strävar efter att bidra till en mer tillgänglig cancervård. ChemoTechs aktier (CMOTEC B) är noterade på Nasdaq First North i Stockholm och Västra Hamnen Corporate Finance AB är bolagets Certified Adviser. Bolaget har huvudkontor på Medicon Village i Lund, mitt i den medicintekniskt expansiva Öresundsregionen.

Subscribe

Documents & Links